Allscripts Healthcare Solutions (Nasdaq: MDRX ) reported earnings on Nov. 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Allscripts Healthcare Solutions missed estimates on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped slightly and GAAP earnings per share dropped significantly.
Margins shrank across the board.
Allscripts Healthcare Solutions tallied revenue of $360.7 million. The 18 analysts polled by S&P Capital IQ expected to see sales of $377.0 million on the same basis. GAAP reported sales were 2.2% lower than the prior-year quarter's $368.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.23. The 20 earnings estimates compiled by S&P Capital IQ forecast $0.22 per share. GAAP EPS of $0.05 for Q3 were 55% lower than the prior-year quarter's $0.11 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 43.5%, 180 basis points worse than the prior-year quarter. Operating margin was 5.6%, 670 basis points worse than the prior-year quarter. Net margin was 2.6%, 310 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $387.5 million. On the bottom line, the average EPS estimate is $0.26.
Next year's average estimate for revenue is $1.50 billion. The average EPS estimate is $0.76.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 445 members out of 473 rating the stock outperform, and 28 members rating it underperform. Among 110 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 104 give Allscripts Healthcare Solutions a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Allscripts Healthcare Solutions is hold, with an average price target of $11.68.
More Expert Advice from The Motley Fool
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock in our brand-new free report: "The Motley Fool's Top Stock for 2013
." I invite you to take a copy, free for a limited time. Just click here
to access the report and find out the name of this under-the-radar company.